Top Markets
#1 MowCat MowCat +631.35%
#2 龙虾 (Lobster) 龙虾 (Lobster) +79.42%
#3 Magma Finance Magma Finance +40.29%
#4 DeXe DeXe +35.60%
#5 Akedo Akedo +28.32%
#6 Cortex Cortex +23.99%
#7 SIXSEVEN SIXSEVEN +22.24%
#8 MarsCoin MarsCoin +18.02%
#9 OpenEden OpenEden +16.05%
#10 Pons Pons +15.08%
Coin of the day
MowCat MowCat
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Classifica tra le azioni #7948
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Prezzo delle azioni
$3.11
Capitalizzazione di mercato
$1.41B
Variazione (1 giorno)
-1.97%
Variazione (1 anno)
-57.22%
Paese
CN
Scambia Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Categoria

Healthcare
Ricavi di Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Staidson (Beijing) BioPharmaceuticals Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Staidson (Beijing) BioPharmaceuticals Co., Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH